Hai-Dong Zhu

Dr. Hai-Dong Zhu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
BZBin-Yan Zhong
Bin-Yan Zhong
ZJZhi-Cheng Jin
Zhi-Cheng Jin
JCJian-Jian Chen
Jian-Jian Chen
HZHai-Dong Zhu
Hai-Dong Zhu
XZXiao-Li Zhu
Xiao-Li Zhu
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line recommendation for intermediate-stage HCC. In real-world clinical practice, TACE also plays an important role in early- and advanced-stage HCC. This review article by the experts from Chinese Liver Cancer Clinical Study Alliance (CHANCE) summarizes the available clinical evidence pertaining to the current application of TACE in patients with early-, intermediate-, and advanced-stage HCC. In addition, combination of TACE with other treatment modalities, especially immunotherapy, is reviewed.

26 April 2022 in Acta Biomaterialia
Verified
Journal Article
Closed access
LLLin-Lin Liu
Lin-Lin Liu
JQJuan Qin
Juan Qin
CZChu Hui Zeng
Chu Hui Zeng
RDRui-Jie Du
Rui-Jie Du
TPTao Pan
Tao Pan
GTGao-Jun Teng
Gao-Jun Teng

12 April 2023 in International Journal of Surgery
Verified
Journal Article
Open access
JLJian Lu
Jian Lu
JGJinhe Guo
Jinhe Guo
JJJiansong Ji
Jiansong Ji
YLYu-Liang Li
Yu-Liang Li
WLWei-Fu Lv
Wei-Fu Lv
GTGao-Jun Teng
Gao-Jun Teng
Background and Aim: Treatment strategy for hepatocellular carcinoma (HCC) and Vp4 [main trunk] portal vein tumor thrombosis (PVTT) remains limited due to posttreatment liver failure. We aimed to assess the efficacy of irradiation stent placement with 125I plus transcatheter arterial chemoembolization (TACE) (ISP-TACE) compared to sorafenib plus TACE (Sora-TACE) in these patients. Methods: In this multicenter randomized controlled trial, participants with HCC and Vp4 PVTT without extrahepatic metastases were enrolled from November 2018 to July 2021 at 16 medical centers. The primary endpoint was overall survival (OS). The secondary endpoints were hepatic function, time to symptomatic progression, patency of portal vein, disease control rate, and treatment safety. Results: Of 105 randomized participants, 51 were assigned to the ISP-TACE group, and 54 were assigned to the Sora-TACE group. The median OS was 9.9 months versus 6.3 months (95% CI: 0.27–0.82; P=0.01). Incidence of acute hepatic decompensation was 16% (8 of 51) versus 33% (18 of 54) (P=0.036). The time to symptomatic progression was 6.6 months versus 4.2 months (95% CI: 0.38–0.93; P=0.037). The median stent patency was 7.2 months (interquartile range, 4.7–9.3) in the ISP-TACE group. The disease control rate was 86% (44 of 51) versus 67% (36 of 54) (P=0.018). Incidences of adverse events at least grade 3 were comparable between the safety populations of the two groups: 16 of 49 (33%) versus 18 of 50 (36%) (P=0.73). Conclusion: Irradiation stent placement plus TACE showed superior results compared with sorafenib plus TACE in prolonging OS in patients with HCC and Vp4 PVTT.

19 February 2024 in United European Gastroenterology Journal
Verified
Journal Article
Open access
JCJian‐Jian Chen
Jian‐Jian Chen
ZJZhi‐Cheng Jin
Zhi‐Cheng Jin
BZBin‐Yan Zhong
Bin‐Yan Zhong
WFWenzhe Fan
Wenzhe Fan
WZWei‐Hua Zhang
Wei‐Hua Zhang
HZHai-Dong Zhu
Hai-Dong Zhu
Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer‐related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real‐world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.

6 February 2026 in eClinicalMedicine
Verified
Journal Article
Open access
JCJian-Jian Chen
Jian-Jian Chen
ZJZhi-Cheng Jin
Zhi-Cheng Jin
JZJia-Wei Zhou
Jia-Wei Zhou
RDRong Ding
Rong Ding
JTJun Tie
Jun Tie
GTGao-Jun Teng
Gao-Jun Teng
This study aimed to assess the clinical outcomes of transarterial chemoembolization (TACE) with immune checkpoint inhibitors (ICIs) plus vascular endothelial growth factor (VEGF) inhibitors or tyrosine kinase inhibitors (TKIs) (combination therapy) versus TACE monotherapy as a first-line treatment for intermediate-stage hepatocellular carcinoma (HCC). This nationwide, retrospective cohort study employed a target trial emulation framework with a cloning-censoring-weighting approach. Patients with intermediate-stage HCC receiving either combination therapy or TACE monotherapy between January 2018 and December 2022 in China were included. Co-primary outcomes were overall survival (OS) and progression-free survival (PFS) per modified Response Evaluation Criteria in Solid Tumors (mRECIST), assessed using restricted mean survival time (RMST). Hazard ratio (HR) was additionally estimated using Cox proportional hazards models for reference. For both RMST and HR, 95% CIs were obtained by bootstrapping. Secondary outcomes included PFS per RECIST 1.1, objective response rate (ORR) per both mRECIST and RECIST 1.1, and safety. This study is registered at ClinicalTrials.gov (NCT05332496). A total of 941 patients were included in the study, with 308 (32.7%) receiving combination therapy, and 633 (67.3%) receiving TACE monotherapy. Median OS was 32.9 with combination therapy versus 23.0 months with TACE monotherapy, with an RMST difference of 9.2 months (95% CI 4.5–14.3, bootstrapped p < 0.001; HR 0.57 [95% CI 0.43–0.70]). Median PFS was 18.0 and 12.9 months in the respective groups, with an RMST difference of 6.7 months (95% CI 3.3–10.7, bootstrapped p = 0.001; HR 0.70 [95% CI 0.58–0.82]). Combination therapy also yielded a higher ORR per mRECIST (60.5% versus 44.3%; p < 0.001). Similar results for PFS and ORR were observed when assessed using RECIST 1.1. Grade ≥3 adverse events occurred in 64 (20.8%) and 43 (6.8%) patients, respectively. Combining TACE with ICIs and VEGF inhibitors or TKIs was associated with improved OS and PFS than TACE monotherapy, with an acceptable safety profile, supporting its potential as a first-line treatment strategy for intermediate-stage HCC. 10.13039/501100001809 National Natural Science Foundation of China (82130060, 82502493), 10.13039/501100002858 China Postdoctoral Science Foundation (2025M772071), Jiangsu Provincial Basic Research Program Natural Science Foundation-Frontier Leading Technology Basic Research Project (BK20232008), Jiangsu Provincial Medical Innovation Center (CXZX202219), Postdoctoral Fellowship Program of CPSF (GZC20251385), and Natural Science Foundation of Jiangsu Province (BK20251687).

1 April 2024 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
CWCheng Wang
Cheng Wang
LGLi Guo
Li Guo
JZJianjun Zhu
Jianjun Zhu
LZLifeng Zhu
Lifeng Zhu
CLChichi Li
Chichi Li
ZJZhongliang Jiang
Zhongliang Jiang
Cancer, with high morbidity and high mortality, is one of the major burdens threatening human health globally. Intervention procedures via percutaneous puncture have been widely used by physicians due to its minimally invasive surgical approach. However, traditional manual puncture intervention depends on personal experience and faces challenges in terms of precisely puncture, learning-curve, safety and efficacy. The development of puncture interventional surgery robotic (PISR) systems could alleviate the aforementioned problems to a certain extent. This paper attempts to review the current status and prospective of PISR systems for thoracic and abdominal application. In this review, the key technologies related to the robotics, including spatial registration, positioning navigation, puncture guidance feedback, respiratory motion compensation, and motion control, are discussed in detail.